Cardiovascular Research Advance Access first published online on November 30, 2007
This version [Corrected Proof] published online on January 11, 2008
Cardiovascular Research, doi:10.1093/cvr/cvm079
Sarcomeric dysfunction in heart failure
1 Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands
2 Experimental Cardiology, Thoraxcenter, Cardiovascular Research School COEUR, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
3 Muscle Research Unit, Institute for Biomedical Research, The University of Sydney, Sydney, Australia
* Corresponding author. Tel: + 31 20 4448123; fax: +31 20 4448255. E-mail address: j.vandervelden{at}vumc.nl
Sarcomeric dysfunction plays a central role in reduced cardiac pump function in heart failure. This review focuses on the alterations in sarcomeric proteins in diseased myocardium that range from altered isoform expression to post-translational protein changes such as proteolysis and phosphorylation. Recent studies in animal models of heart failure and human failing myocardium converge and indicate that sarcomeric dysfunction, including altered maximum force development, Ca2+ sensitivity, and increased passive stiffness, largely originates from altered protein phosphorylation, caused by neurohumoral-induced alterations in the kinase–phosphatase balance inside the cardiomyocytes. Novel therapies, which specifically target phosphorylation sites within sarcomeric proteins or the kinases and phosphatases involved, might improve cardiac function in heart failure.
KEYWORDS Sarcomere; Cardiomyocyte; Contractility; Heart failure
Time for primary review: 27 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
D. J. Duncker, N. M. Boontje, D. Merkus, A. Versteilen, J. Krysiak, G. Mearini, A. El-Armouche, V. J. de Beer, J. M.J. Lamers, L. Carrier, et al. Prevention of Myofilament Dysfunction by {beta}-Blocker Therapy in Postinfarct Remodeling Circ Heart Fail, May 1, 2009; 2(3): 233 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. de Waard, J. van der Velden, N. M. Boontje, D. H. W. Dekkers, R. van Haperen, D. W. D. Kuster, J. M. J. Lamers, R. de Crom, and D. J. Duncker Detrimental effect of combined exercise training and eNOS overexpression on cardiac function after myocardial infarction Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1513 - H1523. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. van Dijk, D. Dooijes, C. dos Remedios, M. Michels, J. M.J. Lamers, S. Winegrad, S. Schlossarek, L. Carrier, F. J. ten Cate, G. J.M. Stienen, et al. Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy: Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction Circulation, March 24, 2009; 119(11): 1473 - 1483. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Solaro Multiplex Kinase Signaling Modifies Cardiac Function at the Level of Sarcomeric Proteins J. Biol. Chem., October 3, 2008; 283(40): 26829 - 26833. [Full Text] [PDF] |
||||
![]() |
R. J. Solaro and P. P. de Tombe Review focus series: sarcomeric proteins as key elements in integrated control of cardiac function Cardiovasc Res, March 1, 2008; 77(4): 616 - 618. [Full Text] [PDF] |
||||




